Page last updated: 2024-11-11

finrozole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

finrozole: an aromatase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918277
SCHEMBL ID2138489
MeSH IDM0288512

Synonyms (14)

Synonym
finrozole
mpv-2213ad
4-[(1r,2s)-3-(4-fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
finrozole [inn]
160146-17-8
unii-40028khq6b
p-((1rs,2sr)-3-(p-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1-yl)propyl)benzonitrile
benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1- yl)propyl)-, (r*,s*)-(+-)-
40028khq6b ,
SCHEMBL2138489
benzonitrile, 4-((1r,2s)-3-(4-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1-yl)propyl)-, rel-
DTXSID90166806
Q15633964
AKOS040748353

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with finrozole, a specific aromatase inhibitor, caused an involution of the differentiated phenotype of the mammary gland, marked by the disappearance of alveolar structures and the majority of the tertiary side branches of the ducts."( Mammary gland development in transgenic male mice expressing human P450 aromatase.
Ahonen, T; Li, X; Mäkelä, S; Poutanen, M; Santti, R; Streng, T; Wärri, A, 2002
)
0.65

Pharmacokinetics

ExcerptReferenceRelevance
" The Cmax values increased as the dose increased."( Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men.
Ahokoski, O; Halonen, K; Huupponen, R; Irjala, K; Kangas, L; Manninen, P; Salminen, E; Scheinin, H; Taalikka, M, 2001
)
0.63
"The absorption of finrozole from the tablet formulation was relatively rapid, and the apparent elimination half-life was longer after the tablet than after the solution, probably reflecting overlap of the absorption with the elimination phase."( Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men.
Ahokoski, O; Halonen, K; Huupponen, R; Irjala, K; Kangas, L; Manninen, P; Salminen, E; Scheinin, H; Taalikka, M, 2001
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's8 (66.67)29.6817
2010's1 (8.33)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.90 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (38.46%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (61.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]